{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:07:43Z","timestamp":1773392863070,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>High recurrence rates of Stages II and IIIA melanoma make close follow\u2010up essential, especially with new adjuvant therapies for metastatic disease. However, there are currently no consensus guidelines for routine imaging for Stages IIB, IIC, and IIIA melanoma. The study's aim is to determine the utility of\u00a0<jats:sup>18<\/jats:sup>F\u2010fluorodeoxyglucose (<jats:sup>18<\/jats:sup>F\u2010FDG) positron emission tomography\/computed tomography\u00a0(PET\/CT) for detecting asymptomatic recurrence of melanoma after primary surgical resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 158 patients with the American Joint Committee on Cancer 8th edition Stages IIB, IIC, or IIIA cutaneous melanoma who underwent an <jats:sup>18<\/jats:sup>F\u2010FDG PET\/CT from 2010 to 2020. We retrospectively analyzed clinical data after a median follow\u2010up time of 39 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We calculated a positive predictive value (PPV) of 32% (95% confidence interval: 11%\u201353%) for 154 routine PET\/CTs, including six true positives and 13 false positives (FPs). PPV was 33% for Stage IIB, 50% for Stage IIC, and 14% for Stage IIIA. FPs were mostly benign or inflammatory foci (75%), and some other malignancies were found (21%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This cohort of patients imaged for high\u2010risk melanoma demonstrated a high FP\u00a0rate and low PPV. These findings suggest that routine surveillance with <jats:sup>18<\/jats:sup>F\u2010FDG PET\/CT may not be indicated for monitoring recurrence in this population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.26737","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T15:38:21Z","timestamp":1636213101000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["<sup>18<\/sup>F\u2010FDG positron emission tomography\u2013computed tomography\u00a0has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high\u2010risk Stages IIB, IIC, and IIIA melanoma"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-8807","authenticated-orcid":false,"given":"Zachary J.","family":"Jaeger","sequence":"first","affiliation":[{"name":"Office of Medical Student Education Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3196-2766","authenticated-orcid":false,"given":"Gregory A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Section of Surgical Oncology, Department of Surgery Washington University School of Medicine St. Louis Missouri USA"},{"name":"Alvin J. Siteman Comprehensive Cancer Center Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-1831","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-265X","authenticated-orcid":false,"given":"Joyce C.","family":"Mhlanga","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-2819","authenticated-orcid":false,"given":"Lynn A.","family":"Cornelius","sequence":"additional","affiliation":[{"name":"Alvin J. Siteman Comprehensive Cancer Center Washington University School of Medicine St. Louis Missouri USA"},{"name":"Division of Dermatology, Department of Medicine Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6176-8943","authenticated-orcid":false,"given":"Ryan C.","family":"Fields","sequence":"additional","affiliation":[{"name":"Section of Surgical Oncology, Department of Surgery Washington University School of Medicine St. Louis Missouri USA"},{"name":"Alvin J. Siteman Comprehensive Cancer Center Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Cancer Stats: Melanoma of the Skin. NIH National Cancer Institute.https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html#ref11. Published 2020. Accessed March 1 2021."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26214"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa008"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08407-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5642-0"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00404-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.055"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02110"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa012"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_239283"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32598-8"},{"key":"e_1_2_10_19_1","unstructured":"Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)): Melanoma: Cutaneous.2021."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2010.09.009"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2017.02.070"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1213879"},{"issue":"6","key":"e_1_2_10_23_1","first-page":"255","article-title":"The value of FDG PET\/CT for follow\u2010up of patients with melanoma: a retrospective analysis","volume":"7","author":"Vensby PH","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"e_1_2_10_24_1","first-page":"17","article-title":"Positron emission tomography in the follow\u2010up of cutaneous malignant melanoma patients: a systematic review","volume":"4","author":"Danielsen M","year":"2013","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-018-0537-6"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy124"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02252-2"},{"key":"e_1_2_10_28_1","volume-title":"AJCC Cancer Staging System","author":"American Joint Committee on Cancer","year":"2018"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07311-0"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0003"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13852"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02306"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpsurg.2021.101030"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa009"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2034861"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.010"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5768-8"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e21612"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471012666191015100106"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32833716f9"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1229"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10570-5"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-200409000-00003"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3060"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072149"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp405"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037857"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.26737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.26737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.26737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:02:23Z","timestamp":1693213343000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.26737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/jso.26737"],"URL":"https:\/\/doi.org\/10.1002\/jso.26737","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"2021-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}